Targeting the Redox Landscape in Cancer Therapy

Research output: Contribution to journal › Review › Research › peer-review

Standard

Targeting the Redox Landscape in Cancer Therapy. / Narayanan, Dilip; Ma, Sana; Özcelik, Dennis.

In: Cancers, Vol. 12, No. 7, 1706, 2020.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Narayanan, D, Ma, S & Özcelik, D 2020, 'Targeting the Redox Landscape in Cancer Therapy', Cancers, vol. 12, no. 7, 1706. https://doi.org/10.3390/cancers12071706

APA

Narayanan, D., Ma, S., & Özcelik, D. (2020). Targeting the Redox Landscape in Cancer Therapy. Cancers, 12(7), [1706]. https://doi.org/10.3390/cancers12071706

Vancouver

Narayanan D, Ma S, Özcelik D. Targeting the Redox Landscape in Cancer Therapy. Cancers. 2020;12(7). 1706. https://doi.org/10.3390/cancers12071706

Author

Narayanan, Dilip ; Ma, Sana ; Özcelik, Dennis. / Targeting the Redox Landscape in Cancer Therapy. In: Cancers. 2020 ; Vol. 12, No. 7.

Bibtex

@article{a396c854fb4644b6a4077cb945e46199,
title = "Targeting the Redox Landscape in Cancer Therapy",
abstract = "Reactive oxygen species (ROS) are produced predominantly by the mitochondrial electron transport chain and by NADPH oxidases in peroxisomes and in the endoplasmic reticulum. The antioxidative defense counters overproduction of ROS with detoxifying enzymes and molecular scavengers, for instance, superoxide dismutase and glutathione, in order to restore redox homeostasis. Mutations in the redox landscape can induce carcinogenesis, whereas increased ROS production can perpetuate cancer development. Moreover, cancer cells can increase production of antioxidants, leading to resistance against chemo- or radiotherapy. Research has been developing pharmaceuticals to target the redox landscape in cancer. For instance, inhibition of key players in the redox landscape aims to modulate ROS production in order to prevent tumor development or to sensitize cancer cells in radiotherapy. Besides the redox landscape of a single cell, alternative strategies take aim at the multi-cellular level. Extracellular vesicles, such as exosomes, are crucial for the development of the hypoxic tumor microenvironment, and hence are explored as target and as drug delivery systems in cancer therapy. This review summarizes the current pharmaceutical and experimental interventions of the cancer redox landscape.",
author = "Dilip Narayanan and Sana Ma and Dennis {\"O}zcelik",
year = "2020",
doi = "10.3390/cancers12071706",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "M D P I AG",
number = "7",

}

RIS

TY - JOUR

T1 - Targeting the Redox Landscape in Cancer Therapy

AU - Narayanan, Dilip

AU - Ma, Sana

AU - Özcelik, Dennis

PY - 2020

Y1 - 2020

N2 - Reactive oxygen species (ROS) are produced predominantly by the mitochondrial electron transport chain and by NADPH oxidases in peroxisomes and in the endoplasmic reticulum. The antioxidative defense counters overproduction of ROS with detoxifying enzymes and molecular scavengers, for instance, superoxide dismutase and glutathione, in order to restore redox homeostasis. Mutations in the redox landscape can induce carcinogenesis, whereas increased ROS production can perpetuate cancer development. Moreover, cancer cells can increase production of antioxidants, leading to resistance against chemo- or radiotherapy. Research has been developing pharmaceuticals to target the redox landscape in cancer. For instance, inhibition of key players in the redox landscape aims to modulate ROS production in order to prevent tumor development or to sensitize cancer cells in radiotherapy. Besides the redox landscape of a single cell, alternative strategies take aim at the multi-cellular level. Extracellular vesicles, such as exosomes, are crucial for the development of the hypoxic tumor microenvironment, and hence are explored as target and as drug delivery systems in cancer therapy. This review summarizes the current pharmaceutical and experimental interventions of the cancer redox landscape.

AB - Reactive oxygen species (ROS) are produced predominantly by the mitochondrial electron transport chain and by NADPH oxidases in peroxisomes and in the endoplasmic reticulum. The antioxidative defense counters overproduction of ROS with detoxifying enzymes and molecular scavengers, for instance, superoxide dismutase and glutathione, in order to restore redox homeostasis. Mutations in the redox landscape can induce carcinogenesis, whereas increased ROS production can perpetuate cancer development. Moreover, cancer cells can increase production of antioxidants, leading to resistance against chemo- or radiotherapy. Research has been developing pharmaceuticals to target the redox landscape in cancer. For instance, inhibition of key players in the redox landscape aims to modulate ROS production in order to prevent tumor development or to sensitize cancer cells in radiotherapy. Besides the redox landscape of a single cell, alternative strategies take aim at the multi-cellular level. Extracellular vesicles, such as exosomes, are crucial for the development of the hypoxic tumor microenvironment, and hence are explored as target and as drug delivery systems in cancer therapy. This review summarizes the current pharmaceutical and experimental interventions of the cancer redox landscape.

U2 - 10.3390/cancers12071706

DO - 10.3390/cancers12071706

M3 - Review

C2 - 32605023

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 1706

ER -

ID: 244444772